Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid A Mayer

Showing results (21-30 of 147) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Is There a Future for AKT Inhibitors in the Treatment of Cancer?Valerie M Jansen, Ingrid A Mayer, Carlos L Arteaga
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Triple-Negative Breast Cancer: Breast Tumors With an Identity CrisisSara E Nunnery, Ingrid A Mayer, Justin M Balko
Cancer Metastasis Reviews|November 30, 2016
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatmentAngel Guerrero-Zotano, Ingrid A Mayer, Carlos L Arteaga
Breast Cancer Research : BCR|January 9, 2009
Evaluation of biological agents targeted at early-stage diseaseMarta Guix, Ingrid A Mayer, Ingrid M Meszoely, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Novel Targeted Agents and Immunotherapy in Breast CancerIngrid A Mayer, Rebecca Dent, Tira Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
New strategies for triple-negative breast cancer--deciphering the heterogeneityIngrid A Mayer, Vandana G Abramson, Brian D Lehmann, et al.
Nature Reviews. Clinical Oncology|May 18, 2016
Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseGiampaolo Bianchini, Justin M Balko, Ingrid A Mayer, et al.
Medical Oncology (Northwood, London, England)|April 9, 2013
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case reportWade Iams, Kathyrn Eby Beckermann, Anne T Neff, et al.
Journal of Leukocyte Biology|October 22, 2020
At the Bedside: Profiling and treating patients with CXCR4-expressing cancersMiguel Martin, Ingrid A Mayer, Annemiek M E Walenkamp, et al.
Journal of Cancer Survivorship : Research and Practice|May 11, 2021
Subjective cognition and mood in persistent chemotherapy-related cognitive impairmentJennifer N Vega, Kimberly M Albert, Ingrid A Mayer, et al.
Pageof 15

Showing results (21-30 of 147) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2016
Is There a Future for AKT Inhibitors in the Treatment of Cancer?Valerie M Jansen, Ingrid A Mayer, Carlos L Arteaga
Cancer Journal (Sudbury, Mass.)|January 21, 2021
Triple-Negative Breast Cancer: Breast Tumors With an Identity CrisisSara E Nunnery, Ingrid A Mayer, Justin M Balko
Cancer Metastasis Reviews|November 30, 2016
PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatmentAngel Guerrero-Zotano, Ingrid A Mayer, Carlos L Arteaga
Breast Cancer Research : BCR|January 9, 2009
Evaluation of biological agents targeted at early-stage diseaseMarta Guix, Ingrid A Mayer, Ingrid M Meszoely, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Novel Targeted Agents and Immunotherapy in Breast CancerIngrid A Mayer, Rebecca Dent, Tira Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 19, 2014
New strategies for triple-negative breast cancer--deciphering the heterogeneityIngrid A Mayer, Vandana G Abramson, Brian D Lehmann, et al.
Nature Reviews. Clinical Oncology|May 18, 2016
Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseGiampaolo Bianchini, Justin M Balko, Ingrid A Mayer, et al.
Medical Oncology (Northwood, London, England)|April 9, 2013
Thrombotic microangiopathy during docetaxel, trastuzumab, and carboplatin chemotherapy for early-stage HER2+ breast cancer: a case reportWade Iams, Kathyrn Eby Beckermann, Anne T Neff, et al.
Journal of Leukocyte Biology|October 22, 2020
At the Bedside: Profiling and treating patients with CXCR4-expressing cancersMiguel Martin, Ingrid A Mayer, Annemiek M E Walenkamp, et al.
Journal of Cancer Survivorship : Research and Practice|May 11, 2021
Subjective cognition and mood in persistent chemotherapy-related cognitive impairmentJennifer N Vega, Kimberly M Albert, Ingrid A Mayer, et al.
Pageof 15